IJSTR

International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
0.2
2019CiteScore
 
10th percentile
Powered by  Scopus
Scopus coverage:
Nov 2018 to May 2020

CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT

IJSTR >> Volume 6 - Issue 12, December 2017 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



A Randomized Open Label Comparative Clinical Study Of A Probiotic Against A Symbiotic In The Treatment Of Acute Diarrhea In Children

[Full Text]

 

AUTHOR(S)

Ramchandra Bastola, Bhawana Sigdel Bastola, Rupa Gurung , Jagat Jeevan Ghimire, Shree Krishna shrestha

 

KEYWORDS

Probiotic, Symbiotic, diarrhea, children

 

ABSTRACT

Objective: To evaluate the safety, efficacy and tolerability of a probiotic against a symbiotic in reducing the frequency and the duration of acute diarrhea. Methods: One hundred children aged 6 months to 6 years, with acute diarrhea, admitted in the Pediatric ward of Pokhara Academy of Health Sciences(PAHS) were recruited in the study. Group A (n = 50) received standard therapy plus probiotic 5 m (Enterogermina®) twice-daily for 7 days. Group B (n = 50) received standard treatment plus symbiotic 5 mL (Bifilac® dry syrup) twice-daily for 7 days. Patients were assessed for diarrhea and dehydration. Results: The frequency of diarrhea was reduced from 9.03 on Day 1 to 0.81 on Day 3 in Group B, compared with 10.1 on Day 1 to 6.24 on Day 3 in Group A. On comparing the two groups on Day 3, Group A produced a statistically significant reduction in the frequency of diarrhea. Similarly, there was a statistically significant reduction in the duration of diarrhea on comparing Group A with Group B. The mean duration of diarrhea was 36.2 hours in Group B, compared with 72.6 hours in Group A. The adverse events were mild and no serious adverse effects were reported. Conclusion: From our study, it can be concluded that the symbiotic is more effective in reducing the frequency and duration of diarrhea then the probiotic and is well-tolerated.

 

REFERENCES

[1] Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet. 2003;361(9376): 2226-34.

[2] Liu L, Johnson HL, Cousens S, Black RE, et al; Child Health Epidemiology Reference Group of WHO and UNICEF "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385(9963):117-71.

[3] WHO/UNICEF Joint Statement. Definition of diarrhoea. The United Nations Children´s Fund/World Health Organization, 2004. WHO/FCH/CAH/04.7.

[4] Hoque KM, Binder HJ. Zinc in the treatment of acute diarrhea: current status and assessment. Gastroenterology. 2006;130(7):2201-5.

[5] Reduced Osmolarity Oral Rehydration Salts (ORS) formulation. A report from a meeting of experts jointly organized by UNICEF and WHO. UNICEF House, New York, USA, 18 July, 2001. WHO/FCH/CAH/0.1.22.

[6] Szajewska H, Setty M, Mrukowicz J, Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr. 2006;42(5):454-75.

[7] Sanders ME. Impact of probiotics on colonizing microbiota of the gut. J Clin Gastroenterol. 2011;45 Suppl:S115-9.

[8] Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev. 2004;(2):CD003048.

[9] Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo- controlled trials. Lancet Infect Dis. 2006;6(6):374-82.

[10] Szajewska H, Skorka A, Ruszczynski M, Gieruszczak- Bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25(8):871-81.